Global pharmaceutical company Eli Lilly (NYSE: LLY) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 47.7% year on year to $22.97 billion. The company’s full-year revenue guidance of $86 billion at the midpoint came in 0.6% above analysts’ estimates. Its non-GAAP profit of $8.38 per share was 27.3% above analysts’ consensus estimates.

Is now the time to buy LLY? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Eli Lilly’s second quarter was marked by a positive market reaction, as the company topped Wall Street’s revenue expectations. Management credited growth in key products—especially in cardiometabolic health, oncology, and neuroscience—as drivers of performance. CEO David Ricks pointed to “robust revenue growth across all Key Products and major geographies,” noting the strength of new medicines and expansion in emerging markets. The launch of Foundayo in the U.S. and UAE, along with ongoing investments in manufacturing and R&D, were highlighted as factors supporting the company’s ongoing business momentum.

Looking ahead, Eli Lilly is focused on expanding access to its obesity and diabetes treatments, with particular emphasis on the Medicare GLP-1 Bridge program and the global rollout of Foundayo. Management expects continued uptake in key markets, supported by pipeline advancements such as retatrutide and new vaccine candidates. CFO Lucas Montarce highlighted that “continued strong performance of our Key Products in the first half of 2026” is shaping the full-year outlook, while also acknowledging the impact of recent acquisitions and ongoing regulatory milestones. The company is preparing for multiple clinical trial readouts and regulatory actions in obesity, diabetes, and mental health therapeutics.

Key Insights from Management’s Remarks

Eli Lilly’s management attributed Q2’s results to strong global uptake of new and established medicines, product launches like Foundayo, and major pipeline progress, while noting volume growth in the incretin segment and expanded manufacturing capacity.

• Obesity and diabetes product momentum: Mounjaro and Zepbound saw significant volume-driven growth in the U.S. and international markets, with management citing early success from the Medicare GLP-1 Bridge program and Foundayo launches in the U.S. and UAE.
• Key pipeline advancements: The company reported progress on multiple late-stage clinical trials, including positive Phase 3 results for retatrutide in obesity and related indications. Management also highlighted regulatory submissions and approvals for new indications in diabetes, Alzheimer’s, and atopic dermatitis.
• Business development and M&A activity: Recent acquisitions in infectious diseases and mental health (such as AtaiBeckley and Curevo) reflect a strategy to broaden the pipeline beyond core therapeutic areas, with management emphasizing the potential to address large unmet needs.
• Geographic expansion: Management noted robust Mounjaro uptake in China, Korea, Germany, and Mexico, and indicated that securing broader reimbursement and regulatory approvals will be critical for sustaining growth outside the U.S.
• Manufacturing scale-up: Eli Lilly opened new manufacturing facilities in Indiana and Ireland to meet rising demand, particularly for genetic medicines and high-growth therapeutics, aiming to ensure consistent supply for global rollouts.

Drivers of Future Performance

Management’s outlook centers on expanding access to obesity and diabetes therapies, pipeline progress, and integrating new acquisitions, while remaining cautious about pricing and reimbursement dynamics.

• Access expansion and reimbursement: The company expects the Medicare GLP-1 Bridge program to bring more American seniors into treatment, while international launches and reimbursement negotiations for Foundayo and other incretins are expected to drive future prescription growth. Management cautioned that reimbursement timelines outside the U.S. can be lengthy, particularly for new therapies.
• Pipeline and clinical milestones: Management highlighted upcoming regulatory submissions for retatrutide, additional Phase 3 trial readouts in obesity and related conditions, and the continued integration of new assets from recent acquisitions. These developments are expected to shape new revenue streams, though timelines for regulatory approval and market adoption remain uncertain.
• Pricing dynamics and market competition: While volume growth remains robust, management acknowledged that pricing pressure—especially from rebates, discounts, and medical exception programs—could constrain net revenue growth. The company also faces competition from generics and rival oral GLP-1s, particularly in emerging markets like India and Brazil.

Catalysts in Upcoming Quarters

Looking ahead, the StockStory team will be monitoring (1) the pace of regulatory approvals and market access for Foundayo and retatrutide, (2) continued international uptake and reimbursement wins for the incretin portfolio, and (3) integration and progress of newly acquired assets in infectious diseases and mental health. Additional clinical trial readouts and the expansion of manufacturing capacity will also be key indicators of execution.

Eli Lilly currently trades at $1,177, up from $1,121 just before the earnings. Is there an opportunity in the stock? The answer lies in our full research report (it’s free).

High Quality Stocks for All Market Conditions

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.